Skip to main content
DataCrafters synthetic data · demonstration

Staff surface Definitions and reviews

Definition library

Every executable definition, side-panel definition and catalogue entry, in three groups by the licence of its source, with its threshold in our own words and the source it is cited to. All are drafts pending review; a definition shows as reviewed only when both a clinical and a coding approval are recorded. Default set library_default_set@1.1.

Local criteria: site choices among published definitions and named local variants of the side-panel definitions, each with a change record, two approvals and an outcome preview.

Coder worklist

Core definitions: sources that are U.S. government works (public domain) or openly licensed (CC BY, with attribution). The product stands on these. 31 executable, 4 side-panel, 3 kidney-check rules (their citations are re-sourced with their next version), 3 catalogue.

Setting: show extended capabilities on clinician screens

Current on clinician screens: Off (default) When on, findings from extended definitions appear on the side panel and the per-note screen under their own heading, after the core findings. Off or on, every check runs and replays the same, and the coder view shows both groups. The guided demo's four cases are unaffected.

CDI or coding staff can change this setting: switch the demo user.

Licence status

Thresholds are stated in our own words. Verbatim text is kept only from U.S. government works and openly licensed (CC BY) sources, with the attribution the licence asks for; copyrighted guidelines are cited by title, body and year, with a locator. No endorsement by the cited bodies is implied. This is not legal advice: counsel should review before commercial release.

Cancer-treatment adverse-event grading scale (NCI CTCAE): off by default

CTCAE grades describe adverse events in people receiving cancer treatment, usually in trials; they are not diagnostic criteria, and several grades depend on the laboratory reference range or on clinical descriptors that are not encoded. Using them outside that setting is a local decision for the clinical reviewer.

Current: Off (default) When on, grading entries are shown only as "another published definition gives …" or as values needing clinical judgement; they never raise a "not stated" item.

CDI or coding staff can change this setting. A clinician account records clinical reviews; a coding or documentation account records coding reviews: switch the demo user.

3 of 41 in “Core definitions” shown.

Malnutrition (GLIM criteria) glim2019_malnutrition catalogue Open licence (CC BY) Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Malnutrition
Tier
2
Licence
Open licence (CC BY)
Source checked
opened on 2026-11-14: PMC6438340 opened 2026-11-14 in the resourcing build: Table 3, Table 4 and section 3.8 read; CC BY 4.0 licence line read. The intake criterion is at or below 50% (the earlier entry said 50%).
Use here
catalogue (not executable)
Edition
2019
Why not executable
Diagnosis needs at least one phenotypic and one etiologic criterion. Reduced muscle mass needs a validated body-composition method or examination, and the etiologic criteria (reduced intake or assimilation, inflammation from acute or chronic disease) are clinical judgements. GLIM also requires prior risk screening. Numbers alone cannot decide it.

GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community

glim2019_malnutrition

In our words: GLIM: at least one physical finding (weight loss over 5% in 6 months or over 10% longer; low BMI; low muscle mass) and one cause (eating half or less of needs for over a week, or less for over 2 weeks; inflammation). Severe: weight loss over 10% in 6 months or over 20% longer, or BMI below 18.5 under 70 / below 20 at 70 and over.

>5% within past 6 months, or>10% beyond 6 months | <20 if <70 years, or <22 if >70 years | Asia: <18.5 if <70 years, or <20 if >70 years | ≤50% of ER >1 week, or any reduction for >2 weeks

Cederholm T et al., GLIM Core Leadership Committee and Working Group (J Cachexia Sarcopenia Muscle 2019;10(1):207-217, doi:10.1002/jcsm.12383) (2019) · Table 3 (phenotypic and etiologic criteria); Table 4 (severity); section 3.8 (diagnosis rule) · source

open licence: CC BY 4.0, attribution: Cederholm T et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019;10(1):207-217, doi:10.1002/jcsm.12383. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). No endorsement by the cited bodies is implied.

See also:
  • GLIM criteria for the diagnosis of malnutrition, GLIM (Clin Nutr 2019;38:1-9; JPEN 2019) (2019) · link — original publications; no open licence per Europe PMC
  • GLIM five-year update, GLIM (2025) — summary only; not opened

Review

Reviewed only when both a clinical review and a coding review are recorded as approved.

Clinical review: none recorded yet.

Coding review: none recorded yet.

Acute kidney injury and chronic kidney disease (kidney rules) kdigo_aki_ckd catalogue U.S. government work Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
AKI / CKD
Tier
1
Licence
U.S. government work
  • GFR bands G1 to G5 including the G3a/G3b split at 45: fact only citation (KDIGO 2024 CKD guideline (numbers restated))
  • albuminuria categories A1 to A3 (A3 at 300 mg/g or more): fact only citation (KDIGO 2012/2024 (numbers restated))
  • AKI stages 1 to 3: open licence (Mahmoud, Erwi, Alfageeh, Cureus 2026;18(5):e109927, Table 2 (CC BY 4.0), restating KDIGO 2012)
  • AKI boundary wording (at least 0.3 mg/dL; at least 1.5 times baseline): fact only citation (KDIGO 2012 AKI guideline, Rec 2.1.1 (numbers restated))
  • 2021 creatinine eGFR equation: public domain (NIDDK, Estimating Glomerular Filtration Rate: Adults (last reviewed May 2025))
Source checked
opened on 2026-11-14: VA/DoD Provider Summary PDF opened 2026-11-14 (Sidebars 2A, 4, 6 read; no copyright statement found); NIDDK equation page and Cureus Table 2 opened the same day. KDIGO texts not re-opened.
Use here
catalogue (not executable)
Edition
2025
Why not executable
Executable already, outside this library: apps/exactdx/rules/kidney (kdigo_aki_2012, kdigo_ckd_2024 with the CKD-EPI equations). Not duplicated here. The rule files keep their own citations until their next version; the permissive sources for them are recorded here and in docs/LIBRARY.md (front conditions).

VA/DoD Clinical Practice Guideline for the Primary Care Management of Chronic Kidney Disease, Provider Summary

kdigo_aki_ckd

In our words: CKD: eGFR below 60, or urine albumin-to-creatinine ratio 30 mg/g or higher, on tests at least 3 months apart. eGFR from the 2021 race-free creatinine equation. AKI: creatinine up at least 0.3 mg/dL in 48 hours, or to at least 1.5 times baseline within 7 days, or low urine output for 6 hours.

Decreased eGFR <60 mL/min/1.73 m2 (GFR categories G3a-G5) for ≥3 months | Albuminuria (UACR ≥30 mg/g) on at least two measurements separated by ≥3 months

U.S. Department of Veterans Affairs and Department of Defense (2025) · Sidebar 2A 'eGFR Calculation' (PDF p. 10); Sidebar 4 'Definition of AKI and AKD' (PDF p. 13); Sidebar 6 'Criteria for CKD' (PDF p. 16) · source

U.S. government work (public domain). No endorsement by the cited bodies is implied.

See also:
  • KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD, KDIGO (Kidney Int 2024;105(4S):S117-S314) (2024), Chapter 1; GFR and albuminuria categories — numbers restated; text, tables and figures not reproduced (CC BY-NC-ND per Europe PMC metadata)
  • KDIGO Clinical Practice Guideline for Acute Kidney Injury, KDIGO (Kidney Int Suppl 2012;2:1-138) (2012), Rec 2.1.1; Table 2 — numbers restated; text not reproduced
  • Acute Kidney Injury in the Intensive Care Unit: Recent Advances, Mahmoud IF, Erwi SM, Alfageeh AM (Cureus 2026;18(5):e109927) (2026), Table 2 'Severity staging system for AKI' · link — open-licence (CC BY 4.0) restatement of the AKI stages; opened 2026-11-14
  • Estimating Glomerular Filtration Rate: Adults, NIDDK (2025), 2021 CKD-EPI Creatinine Equation · link — federal; equation opened 2026-11-14 (no CKD cut-offs on the page)

Review

Reviewed only when both a clinical review and a coding review are recorded as approved.

Clinical review: none recorded yet.

Coding review: none recorded yet.

Heart failure acuity and stage uhf2021_hf_acuity_and_stage catalogue Open licence (CC BY) Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Heart failure acuity
Tier
2
Licence
Open licence (CC BY)
Source checked
opened on 2026-11-14: PMC9254673 opened 2026-11-14: stages and trajectory terms read in sections 1.3 and 2.4.
Use here
catalogue (not executable)
Edition
2022
Why not executable
The universal definition's stages (at risk, pre-HF, HF, advanced HF) and acuity or trajectory (new onset, worsening, persistent, in remission) depend on symptoms, signs, structural disease and response to therapy. Only the EF category is numeric and is executable as uhf2021_hf_ef_category.

Clinical implications of the universal definition for the prevention and treatment of heart failure

uhf2021_hf_acuity_and_stage

In our words: Stage (at risk, pre-HF, HF, advanced HF) and acuity are clinical judgements; the record values are shown for review.

at risk for HF, pre‐HF, HF, and advanced HF in place of the previous stages A–D

Chandramouli C, Stewart S, Almahmeed W, Lam CSP (Clin Cardiol 2022;45(Suppl 1):S2-S12, doi:10.1002/clc.23842) (2022) · Section 1.3 'New universal definition' (stages); section 2.4 (trajectory terms) · source

open licence: CC BY 4.0, attribution: Chandramouli C, Stewart S, Almahmeed W, Lam CSP. Clinical implications of the universal definition for the prevention and treatment of heart failure. Clin Cardiol 2022;45(Suppl 1):S2-S12, doi:10.1002/clc.23842. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). No endorsement by the cited bodies is implied.

See also:
  • The second universal definition of heart failure (2026). What's new?, Biegus J, Ponikowski P (ESC Heart Fail 2026;13(5):xvag240) (2026) · link — edition note: CC BY editorial; not opened in this build (captcha); reported to prefer 'decompensated HF' defined by escalated care
  • Universal Definition and Classification of Heart Failure, HFSA, HFA-ESC and JHFS (J Card Fail 2021;27:387-413) (2021) · link — earlier primary; text not reproduced

Review

Reviewed only when both a clinical review and a coding review are recorded as approved.

Clinical review: none recorded yet.

Coding review: none recorded yet.